Inclusion Criteria:  Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC (Stage IIIB or IV accordingly to American Joint Committee on Cancer [AJCC] classification) at time of capmatinib initiation Presence of a MET dysregulation diagnosed on tumor sample and/or on liquid biopsy Patients who were informed about the study and accepted for their data to be collected. Patients who received at least one dose of treatment with capmatinib as part of the compassionate use program (ATU), whatever the line of treatment. Selection period spans from June 1st 2019 (date of start of French ATU) until August 31st 2021 for first dose of capmatinib. Age >18 y  Exclusion Criteria:  Patients enrolled in a clinical trial assessing treatment with capmatinib. (ATU was granted to patients unable to meet eligibility criteria for on-going recruiting trials, unable to participate to other clinical trials, or because other medical interventions were not considered appropriate or acceptable). Patients who were included in the French Early Access Program (ATU program) but did not receive any capmatinib treatment. Patients who have expressed explicit refusal to collect his or her data Patients with a psychiatric history that hinders the comprehension of the information leaflet Patients under curatorship or guardianship Unability to obtain data collection